A Phase 2 interventional study of lonafarnib and peginterferon alfa-2a in Chronic Hepatitis D Infection, sponsored by EIT Pharma, Inc.. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by EIT Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Twenty-one subjects with chronic delta hepatitis will be randomized to receive one of seven different doses of lonafarnib. Dosing will occur over 4-12 weeks, depending on treatment arm, and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for the treatment duration. Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of seven dose combinations of lonafarnib with and without ritonavir boosting.
43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.
This study's enrollment of 21 is below the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.
Browse Hepatitis D, Chronic studies →EIT Pharma, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females of (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use one of the following acceptable methods throughout the study:
Exclusion Criteria:
History or clinical evidence of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lonafarnib 200 mg BID; n=3
Drug: lonafarnib
lonafarnib 300 mg BID; n=3
Drug: lonafarnib
lonafarnib 100 mg TID; n=3
Drug: lonafarnib
lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3
Drug: lonafarnib · Drug: peginterferon alfa-2a
lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3
Drug: lonafarnib · Drug: peginterferon alfa-2a
lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=2
Drug: lonafarnib · Drug: peginterferon alfa-2a
lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3
Drug: lonafarnib · Drug: ritonavir
antiviral farnesyl transferase inhibitor
Also known as: Sarasar, EBP994
immunomodulator
Also known as: Pegasys, pegylated interferon-alfa, PEG IFN-alfa, PEG IFN-a
CYP 3A4 inhibitor, lonafarnib booster
Also known as: Norvir, RTV
Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy
log HDV RNA decline from baseline to end of treatment (4-12 weeks of lonafarnib-based therapy)
Time frame: 4-12 weeks
| Milestone | Lonafarnib - I | Lonafarnib - II | Lonafarnib - III | Lonafarnib/PEG IFN-a - I | Lonafarnib/PEG IFN-a - II | Lonafarnib/PEG IFN-a - III | Lonafarnib/Ritonavir |
|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Completed | 3 | 3 | 2 | 3 | 3 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 2 | 3 |
log HDV RNA decline from baseline to end of treatment (4-12 weeks of lonafarnib-based therapy)
| log IU/mL | Lonafarnib 200 mg BID | Lonafarnib 300 mg BID | Lonafarnib 100 mg TID | 100 mg BID Lonafarnib/PEG IFN-a | 200 mg BID Lonafarnib/PEG IFN-a | 300 mg BID Lonafarnib/PEG IFN-a | Lonafarnib/Ritonavir |
|---|---|---|---|---|---|---|---|
| Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy | 0.03 (-1.17 to 1.83) | -1.78 (-2.28 to -1.46) | -1.3 (-1.61 to -0.52) | -1.85 (-2.4 to -1.33) | 0 (0 to 0) | 0 (0 to 0) | -1.2 (-1.41 to -0.91) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lonafarnib 200 mg BID | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Lonafarnib 300 mg BID | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Lonafarnib 100 mg TID | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| 100 mg BID Lonafarnib/PEG IFN-a | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| 200 mg BID Lonafarnib/PEG IFN-a | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| 300 mg BID Lonafarnib/PEG IFN-a | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Lonafarnib/Ritonavir | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Lonafarnib 200 mg BID | Lonafarnib 300 mg BID | Lonafarnib 100 mg TID | 100 mg BID Lonafarnib/PEG IFN-a | 200 mg BID Lonafarnib/PEG IFN-a | 300 mg BID Lonafarnib/PEG IFN-a | Lonafarnib/Ritonavir |
|---|---|---|---|---|---|---|---|
| dehydration secondary to vomiting and diarrheaGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/2 | 0/3 |
| Event | Lonafarnib 200 mg BID | Lonafarnib 300 mg BID | Lonafarnib 100 mg TID | 100 mg BID Lonafarnib/PEG IFN-a | 200 mg BID Lonafarnib/PEG IFN-a | 300 mg BID Lonafarnib/PEG IFN-a | Lonafarnib/Ritonavir |
|---|---|---|---|---|---|---|---|
| weight lossInvestigations | 3/3 | 3/3 | 2/3 | 1/3 | 0/3 | 0/2 | 2/3 |
| diarrheaGastrointestinal disorders | 3/3 | 3/3 | 2/3 | 3/3 | 0/3 | 0/2 | 3/3 |
| nauseaGastrointestinal disorders | 3/3 | 3/3 | 2/3 | 3/3 | 0/3 | 0/2 | 3/3 |
| fatigueGeneral disorders | 3/3 | 2/3 | 2/3 | 1/3 | 0/3 | 0/2 | 2/3 |
| vomitingGastrointestinal disorders | 2/3 | 3/3 | 2/3 | 0/3 | 0/3 | 0/2 | 1/3 |
Patients aged 18-65 years with documented HBsAg, anti-delta positivity for at least 6 months, and compensated liver disease were eligible after evaluation for other forms of chronic liver disease. Patients were required to have detectable HDV-RNA levels at screening, platelet counts \>/= 100,000/mm3, absolute neutrophil count \>/= 1,500 /mm3, and international normalized ratio \<1.5. Patients with hepatocellular carcinoma were excluded.
| Age, Continuous(years) | Lonafarnib 200 mg BID | Lonafarnib 300 mg BID | Lonafarnib 100 mg TID | 100 mg BID Lonafarnib/PEG IFN-a | 200 mg BID Lonafarnib/PEG IFN-a | 300 mg BID Lonafarnib/PEG IFN-a | Lonafarnib/Ritonavir | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 59 (57 to 63) | 40 (36 to 46) | 46 (40 to 51) | 41 (22 to 52) | 46 (35 to 53) | 49 (48 to 49) | 51 (42 to 61) | 49 (22 to 63) |
| Sex: Female, Male(Participants) | Lonafarnib 200 mg BID | Lonafarnib 300 mg BID | Lonafarnib 100 mg TID | 100 mg BID Lonafarnib/PEG IFN-a | 200 mg BID Lonafarnib/PEG IFN-a | 300 mg BID Lonafarnib/PEG IFN-a | Lonafarnib/Ritonavir | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 2 | 1 | 0 | 1 | 0 | 7 |
| Male | 1 | 2 | 1 | 2 | 3 | 1 | 3 | 13 |
| Region of Enrollment(participants) | Lonafarnib 200 mg BID | Lonafarnib 300 mg BID | Lonafarnib 100 mg TID | 100 mg BID Lonafarnib/PEG IFN-a | 200 mg BID Lonafarnib/PEG IFN-a | 300 mg BID Lonafarnib/PEG IFN-a | Lonafarnib/Ritonavir | Total |
|---|---|---|---|---|---|---|---|---|
| Turkey | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 20 |
The record gives a start of Nov 2014, a primary completion of Sep 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2022, 7 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lonafarnib
EIT Pharma, Inc.